Chronic kidney disease: The impact of intestinal microorganisms - Brief overview

Immanuel, Peter

Page 25

Journal of MedVerse Research & Practice

nurexus.com

Chronic kidney disease: The impact of intestinal microorganisms -

Brief Overview

Dr. Peter Immanuel

Associate professor, General medicine

Sri Lalithambikai Medical College & Hospital, Chennai

Mail ID: peterimmanuel@gmail.com

Submission Date: 29.12.2024

Accepted Date: 25.01.2025

Published Date: 31.01.2025

access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which

permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source

are credited.

Abstract

Chronic kidney disease (CKD) is associated with progressive impairment of renal function and the

accumulation of metabolic waste products, including uremic retention solutes. Emerging evidence

suggests that alterations in the gut microbiota may influence the production of microbial metabolites,

intestinal barrier function, and systemic inflammatory responses in individuals with CKD. Reduced

kidney function can also alter the intestinal environment, potentially contributing to changes in

microbial composition and metabolite handling. Certain gut-derived compounds, including indoxyl

sulfate and p-cresyl sulfate, have been investigated for their associations with inflammation,

cardiovascular risk, and CKD-related complications. However, the strength of evidence varies across

metabolites, and associations do not necessarily establish causation. This review outlines the

relationship between CKD and gut microbial dysbiosis, discusses potential mechanisms linking

intestinal microorganisms with uremic toxin accumulation, and summarizes emerging microbiota-

targeted interventions. Further research is needed to establish the clinical effectiveness and safety of

these interventions and determine whether modifying the gut microbiota improves meaningful

outcomes in patients with CKD.

Keywords: Chronic Kidney Disease, Gut Microbiota

Introduction

Chronic kidney disease (CKD), which constitutes a persistent and long-term disorder affecting renal

function, is defined as a medical condition that persists for a duration exceeding three months and is

characterized by various structural or functional abnormalities observable within the kidneys [1–4].

These abnormalities serve as critical indicators in the assessment of kidney health. The definitive

diagnosis of CKD is typically established through the identification of pathological findings or the

presence of specific biochemical markers indicative of kidney damage, which may include

irregularities detected in blood or urine composition, or notable deviations in laboratory test

outcomes routinely employed in clinical practice to assess renal function and overall health [4].

Chronic kidney disease is a significant contributor to morbidity and mortality rates among

noncommunicable diseases, and it ranks as the 10th leading cause of death globally, with an

estimated worldwide prevalence ranging from 10% to 16% [1–3]. Currently, it is estimated that

CKD affects over 850 million individuals worldwide, with a substantial proportion of these affected

REVIEW ARTICLE

Page 26

individuals residing in low- and middle-income countries where healthcare resources are often

limited, thus exacerbating the challenges associated with managing and treating this prevalent

condition [5]. In recent years, the relationship between CKD and the gut microbiota has received

increasing research attention. Reduced renal function may alter the intestinal environment, while

microbial metabolism can contribute to the generation of compounds that accumulate when renal

clearance is impaired. Understanding these interactions may help clarify pathways involved in

uremic toxin accumulation and identify potential avenues for further research [6-9].

The gut microbiota contributes to the metabolism of dietary components and endogenous

substances and participates in interactions with the intestinal barrier and host immune system. In

chronic kidney disease, changes in renal function, diet, medication use, and the intestinal

environment may be associated with alterations in microbial composition and activity. These

changes can influence the generation and handling of microbial metabolites, some of which may

accumulate in patients with impaired renal clearance. The relationship is potentially bidirectional:

kidney dysfunction can affect the intestinal environment, while microbial metabolites may

contribute to pathways associated with systemic inflammation. The clinical importance of

individual microbial species and metabolites requires further investigation [5, 10-12].

Gut Microbial Dysbiosis

Gut microbial dysbiosis refers to an alteration in the composition or function of the intestinal

microbial community. In patients with CKD, dysbiosis has been associated with changes in

microbial diversity and the metabolism of dietary and endogenous substrates. These alterations may

influence the generation of gut-derived metabolites and their subsequent accumulation in the

circulation when renal clearance is impaired. However, microbial patterns can differ according to

dietary intake, medication exposure, disease severity, and other patient characteristics.

Consequently, findings from individual studies should not be interpreted as establishing a single

microbial profile applicable to every patient with CKD. Further research is required to determine

which microbial changes are clinically meaningful and whether modifying them improves patient

outcomes [12, 13].

The intestinal microbiota comprises a diverse community of microorganisms, including bacteria,

archaea, viruses, and fungi. Its metabolic activities include the fermentation of dietary substrates

and the transformation of selected compounds, including bile acids and other substances relevant to

host physiology. The composition and function of this community vary between individuals and

may be influenced by diet, medication use, health status, and environmental factors. In CKD,

changes in the intestinal environment may alter microbial metabolism and the production of

metabolites relevant to uremic toxin accumulation. These relationships require interpretation in the

context of the specific populations and methods investigated in each study [14,15,16].

Physiological Changes in CKD

As renal function declines in chronic kidney disease (CKD), the clearance of urea and other

metabolic waste products decreases, resulting in their accumulation in the bloodstream. A greater

proportion of circulating urea may enter the gastrointestinal tract, where microbial urease activity

converts it into ammonia and carbon dioxide [17]. Changes in the intestinal environment may

influence microbial composition and metabolism. Ammonia production and other microbial

processes may alter the intestinal environment and have been investigated for their potential effects

Page 27

on epithelial barrier integrity. Increased intestinal permeability may facilitate the translocation of

bacterial components, including lipopolysaccharides (LPS), into the systemic circulation,

potentially contributing to inflammatory responses in CKD [18]. However, the extent and clinical

significance of these mechanisms require further investigation.

Alterations in the gut microbiota of individuals with CKD have also been associated with changes

in the metabolism of dietary proteins and amino acids. Certain intestinal microorganisms can

metabolize compounds such as tyrosine and tryptophan, contributing to the formation of metabolites

that may accumulate when renal clearance is impaired. Several microbial groups have been

investigated in relation to these processes, including members of the Clostridia class and the

Bacteroidetes group. However, the contribution of individual bacterial species varies, and their

presence alone does not establish that they directly cause CKD progression. Studies have also

reported changes in the abundance of bacterial groups considered potentially beneficial, including

Lactobacillus and Bifidobacterium, although these findings may differ according to diet, medication

use, disease severity, and study population [19].

Gut microbial metabolism involves a range of dietary and endogenous substrates, including amino

acids and compounds such as choline and L-carnitine. These metabolic processes may contribute to

the production of gut-derived metabolites that are being investigated for their associations with

kidney function and systemic health. The relationship between kidney function and the gut

microbiota is potentially bidirectional: impaired renal function can alter the intestinal environment,

while microbial metabolites may influence physiological pathways relevant to CKD [20]. Further

research is needed to clarify the mechanisms involved and determine the clinical significance of

individual metabolites.

Gut microbial dysbiosis refers to changes in the composition or function of the intestinal microbial

community. In patients with CKD, dysbiosis has been associated with alterations in microbial

diversity and the production of selected metabolites. However, these changes are not uniform across

all patients and may be influenced by dietary patterns, medication exposure, comorbidities, and the

stage of kidney disease. Some studies have reported associations between kidney-function measures

and the abundance of bacterial genera such as Prevotella, Faecalibacterium, and Roseburia. The

direction and strength of these associations may vary across populations and study designs.

Reduced microbial diversity has also been investigated in relation to markers of kidney damage,

including the urinary albumin-to-creatinine ratio [5,7,11,12]. These findings indicate a potential

relationship between the gut microbiota and CKD, but further studies are required to establish

causality and determine whether microbiota-targeted interventions can improve clinical outcomes.

Summary

Chronic kidney disease is associated with changes in the intestinal microbial community and the

handling of gut-derived metabolites. Alterations in microbial metabolism may contribute to the

generation of selected uremic solutes, while impaired renal clearance can facilitate their

accumulation. Research has investigated associations between these processes, systemic

inflammation, and cardiovascular complications. However, the strength of evidence differs across

metabolites and clinical outcomes, and observational associations do not establish causality. Dietary

modification and microbiota-targeted interventions, including prebiotics and probiotics, remain

areas of investigation. Further studies are needed to identify clinically relevant microbial changes,

Page 28

clarify underlying mechanisms, and determine whether these interventions improve outcomes in

patients with CKD.

Conclusion

Chronic kidney disease is associated with alterations in gut microbial composition and metabolism

that may influence the production and accumulation of uremic solutes. Interactions between

impaired renal function, the intestinal environment, and microbial activity represent an important

area of ongoing research. Although selected gut-derived metabolites have been associated with

inflammation and CKD-related complications, further evidence is needed to establish their causal

roles and clinical relevance. Future research should evaluate the safety and effectiveness of

microbiota-targeted interventions and determine whether these approaches provide additional

benefits alongside established CKD management. At present, such interventions should not be

presented as proven replacements for standard treatment.

Declaration

Conflict of Interest: The authors declare that they have no competing interests or conflicts of

interest related to this work.

Funding: No external funding was received for this review.

References

1. Centers for Disease Control and Prevention (U.S.). Chronic Kidney Disease Basics

(https://www.cdc.gov/kidneydisease/basics.html). Accessed 5/7/2023.

2. National Kidney Foundation. Chronic Kidney Disease (CKD) Symptoms and Causes

(https://www.kidney.org/atoz/content/about-chronic-kidney-disease). Accessed 5/7/2023.

3. National Institute of Diabetes and Digestive and Kidney Diseases (U.S.). What is Chronic Kidney

Disease? (https://www.niddk.nih.gov/health-information/kidney- disease/chronic-kidney-disease-ckd)

Accessed 5/7/2023.

4. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review.

JAMA. 2019 Oct 1;322(13):1294-1304. doi: 10.1001/jama.2019.14745. PMID: 31573641; PMCID:

PMC7015670.

5. He, M., Wei, W., Zhang, Y. et al. Gut microbial metabolites SCFAs and chronic kidney disease. J

Transl Med 22, 172 (2024).

6. Queeley GL, Campbell ES. Comparing Treatment Modalities for End-Stage Renal Disease: A Meta-

Analysis. Am Health Drug Benefits. 2018 May;11(3):118-127. PMID: 29910844; PMCID:

PMC5973249.

7. Sakaguchi Y, Kaimori JY, Isaka Y. Plant-Dominant Low Protein Diet: A Potential Alternative Dietary

Practice for Patients with Chronic Kidney Disease. Nutrients. 2023 Feb 16;15(4):1002. doi:

10.3390/nu15041002. PMID: 36839360; PMCID: PMC9964049.

8. Shreiner AB, Kao JY, Young VB, Turnbaugh PJ, Ley RE, Mahowald MA, et al. Dicer (E-7): sc-

393328. Cell [Internet]. 2015;69(1):393328.

9. Nallu A, Sharma S, Ramezani A, Muralidharan J, Raj D. Gut microbiome in chronic kidney disease:

challenges and opportunities. Transl Res [Internet]. 2017;179(May):24–37.

10. Iwata Y, Wada T. Gut microbiota and chronic kidney disease. Japanese J Nephrol [Internet].

2017;59(4):545–51.

11. Peters, B. A., Qi, Q., Usyk, M., Daviglus, M. L., Cai, J., Franceschini, N., Lash, J. C. (2023).

Association of the gut microbiome with kidney function and damage in the Hispanic Community

Health Study/Study of Latinos (HCHS/SOL). Gut microbes, 15(1), 2186685.

https://doi.org/10.1080/19490976.2023.2186685

Page 29

12. Ramezani, A., & Raj, D. S. (2014). The gut microbiome, kidney disease, and targeted interventions.

Journal of the American Society of Nephrology : JASN, 25(4), 657–670.

https://doi.org/10.1681/ASN.2013080905

13. Rysz J, Franczyk B, Lawisnki J, Olszeweski R, Cialkowska-Rysz A, Gluba-Brzozka

A. Uremic toxin levels are associated with gut microbiome changes in kidney transplant recipients. Transpl

Int [Internet]. 2021;34(SUPPL 1):231.

14. Gut E, Soulage O, Popkov VA, Zharikova AA, Demchenko EA, Andrianova N V, et al. Citation: Gut

Microbiota as a Source of Uremic Toxins. Toxins Int J Mol Sci [Internet]. 2022;2022:483.

15. Ebrahim, Z., Proost, S., Tito, R. Y., Raes, J., Glorieux, G., Moosa, M. R., & Blaauw,

R. (2022). The Effect of ß-Glucan Prebiotic on Kidney Function, Uremic Toxins and Gut Microbiome in

Stage 3 to 5 Chronic Kidney Disease (CKD) Predialysis Participants: A Randomized Controlled Trial.

Nutrients, 14(4), 805. https://doi.org/10.3390/nu14040805

16. Farnam Nia, S., Nasri, H., Mazaheri Tehrani, S., & Rouzbahani, S. (2024). Ameliorating impact of

berberine on gut microbiota in chronic kidney disease. Journal of Renal Endocrinology.

17. Black, AP; Anjos, JS; Cardozo, A; et al. Does Low-Protein Diet Influence the Uremic Toxin Serum

Levels From the Gut Microbiota in Nondialysis Chronic Kidney Disease Patients. J Ren Nutr. 2018.

28(3) : 1-7

18. Marzocco, S.; Dal Piaz, F.; Di Micco, L.; et al. Very Low Protein Diet Reduces Indoxyl Sulfate Levels

in Chronic Kidney Disease. Blood Purif. 2013. 35 : 196-201

19. Rocchetti, M; Di lorio, BR; Vacca, M; et al. Ketoanalogs’ Effect on Intestinal Microbiota Modulation

and Uremic Toxins Serum Levels in Chronic Kidney Disease (Medika2 Study). J Clin Med. 2021. 10

(4) : 840.

20. Guldris, SC; Parra, EG; Amenos, AC. Gut Microbiota in Chronic Kidney Disease. Nefrologia. 2017.

37(1) : 9-19.